<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03389659</url>
  </required_header>
  <id_info>
    <org_study_id>TianjinCIH20171212</org_study_id>
    <nct_id>NCT03389659</nct_id>
  </id_info>
  <brief_title>XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC</brief_title>
  <official_title>A Randomized, Multicenter, Double-blinded, Phase III Study of Vitamin D3 in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine as First-line Chemotherapy in Previously Untreated Advanced or Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized,multicenter, double-blinded,phase III study. To explore the
      affection of vitamin D3 in combination with oxaliplatin plus fluoropyrimidine versus
      oxaliplatin plus fluoropyrimidine as first-line chemotherapy in previously untreated advanced
      or metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-blined</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>PFS(progression-free survival)</measure>
    <time_frame>5 years</time_frame>
    <description>PFS is defined the time from the date of randomization to the date of disease progression or death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS(overall survival)</measure>
    <time_frame>5 years</time_frame>
    <description>OS is defined the time between the date of randomization and the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>up to 1 year</time_frame>
    <description>disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 1 year</time_frame>
    <description>overall response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>all the adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Vitamin D3</condition>
  <arm_group>
    <arm_group_label>Vitamin D3 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin D3 2000IU (400IU*5pills） po. qd continue to disease progression plus XELOX (oxaliplatin 130mg/m2 d1; capecitabine 1000mg/m2 bid po. d1-14; q3w) or mFOLFOX (oxaliplatin 85mg/m2，d1; leucovorin 400mg/m2，d1；5-fluorouracil 400mg/m2，d1; 5-fluorouracil 2400mg/m2 continue 46h, q2w)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 5 pills po. qd continue to disease progression plus XELOX (oxaliplatin 130mg/m2 d1; capecitabine 1000mg/m2 bid po. d1-14; q3w) or mFOLFOX (oxaliplatin 85mg/m2，d1; leucovorin 400mg/m2，d1；5-fluorouracil 400mg/m2，d1; 5-fluorouracil 2400mg/m2 continue 46h, q2w)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D3</intervention_name>
    <description>vitamin D3 400IU*5pills po. qd continue to disease progression</description>
    <arm_group_label>Vitamin D3 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo 5 pills po. qd continue to disease progression</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent.

          -  males and females, ≥18 years of age

          -  All subjects must have inoperable, advanced or metastatic colorectal cancer and have
             confirmed histologically adenocarcinoma.

          -  Subject must be previously untreated with systemic treatment given as primary therapy
             for advanced or metastatic disease.

          -  Prior adjuvant or neoadjuvant chemotherapy and/or radiotherapy are permitted as long
             as the last administration of the last regimen occurred at least 12 months prior to
             randomization.

          -  ECOG performance status score of 0 or 1.

          -  Subjects must have at least one measurable lesion or evaluable disease by CT of MRI
             per RECIST1.1 criteria.

          -  Screening laboratory values must meet the following criteria in 7days before the first
             day of cycle 1:

               1. Hemoglobin ≥9.0g/dL;

               2. Neutrophils ≥1500/mm3;

               3. Platelet ≥100,000/mm3;

               4. Total Bilirubin ≤1.5*ULN

               5. AST ≤2.5*ULN (or ≤5.0*ULN if liver metastases are present), and ALT ≤2.5*ULN (or
                  ≤5.0*ULN if liver metastases are present)

               6. Serum creatinine ≤1.5*ULN or calculated creatinine clearance ＞50mL/min

          -  Women of childbearing potential must have a negative serum or urine pregnancy test
             within 7 days before randomization. All subjects of childbearing potential must agree
             to follow instructions for method of contraception for the duration of study treatment
             and 6 months after the last dose of study treatment.

          -  Life expectancy ≥3 months.

        Exclusion Criteria:

          -  Concurrent diseases:

               1. Prior malignancy active cancer except for locally curable cancer that have been
                  cured over 5years,or carcinoma in situ.

               2. Known brain metastasis

               3. Any serious or uncontrolled medical disorder or active infection.

               4. Known history of positive test for HIV or AIDS;

               5. Hepatitis B virus or hepatitis C virus is active;

          -  Within 4 weeks before randomization had operation, enlarged area radiotherapy(local
             radiotherapy within 2weeks) and other study drugs.

          -  Subjects with ≥ Grade 2 peripheral neuropathy.

          -  Pregnancy or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ting Deng</last_name>
    <phone>+86 15802243063</phone>
    <email>xymcdengting@126.com</email>
  </overall_contact>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2017</study_first_submitted>
  <study_first_submitted_qc>December 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2018</study_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mCRC</keyword>
  <keyword>oxaliplatin plus fluoropyrimidine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

